#Saudi Arabia #Co-Diagnostics #CoMira #Sudair #Sudair Industrial City

Co-Diagnostics and CoMira's New Venture in Saudi Arabia

The molecular diagnostics landscape in Saudi Arabia is set to experience a significant transformation following the announcement from Co-Diagnostics, Inc. and its joint venture partner, CoMira Diagnostics. On April 2, 2026, the companies shared that they have obtained regulatory approval for establishing a manufacturing facility in Sudair Industrial City, a key industrial hub in the Riyadh region.

Strategic Location and Vision 2030

Sudair Industrial City, managed by the Saudi Authority for Industrial Cities and Technology Zones (MODON), plays an essential role in Saudi Arabia's Vision 2030 strategy. This initiative aims to diversify the economy by strengthening domestic manufacturing capabilities and reducing reliance on imports.

According to Dwight Egan, CEO of Co-Diagnostics, the new facility will significantly contribute to localizing advanced diagnostic technologies in the Kingdom. The facility is expected to support the deployment of Co-Dx's patented PCR platform, aimed at producing molecular diagnostic instruments and assays tailored to the specifics of the regional market.

Commitment to Localization

The establishment of the manufacturing facility reflects CoMira’s commitment to align with the KSA's broader economic objectives. As highlighted by CoMira Diagnostics' CEO, Ihssan Rjoob, the new site represents a foundational milestone signaling a long-term commitment to advancing molecular diagnostics production in the Kingdom. By fostering local content and facilitating domestic production, the joint venture aims to contribute significantly to national healthcare resilience and innovation.

Once operational, CoMira intends to position itself as one of the early domestic manufacturers of molecular diagnostic testing solutions in Saudi Arabia. The facility will allow for faster access to innovative diagnostic technologies while supporting the nation’s healthcare systems with reliable diagnostic options.

Enhancing Regional Capabilities

The capacity of the manufacturing facility is designed to be scalable, thereby enabling the plants to adapt and grow with evolving market demands. Alongside providing advanced diagnostic solutions closer to patients, it will also strengthen the regional supply chain and manufacturing capabilities.

The Co-Dx PCR platform, central to the facility’s operations, is under review by regulatory bodies like the FDA and will enhance the range of diagnostic options available in Saudi Arabia and potentially throughout the Middle East and North Africa.

This new venture signifies a pivotal step in the growth of the molecular diagnostics sector in the country and supports the KSA’s endeavors in making substantial enhancements in healthcare standards.

Moving forward, Co-Diagnostics and CoMira are optimistic about the future and the various possibilities this facility will bring. As both companies continue to navigate the complexities of expanding their operations and achieving regulatory approvals, they remain focused on delivering high-quality diagnostic products to meet the urgent needs of the market.

Overall, Co-Diagnostics and CoMira's partnership marks a promising development in the region’s healthcare landscape, mirroring the broader objectives of Saudi Arabia's Vision 2030 economic initiatives. The approval of the manufacturing facility in Sudair Industrial City sets a new precedent for local innovation and manufacturing in the field of molecular diagnostics.